کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2139715 | 1087913 | 2008 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD)
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
JAK2 V617F mutation is found in a high proportion of MPD patients. We developed a quantitative assay for the detection of the JAK2 mutation and demonstrated its clinical utility in MPD patients who underwent SCT. Sixty percent of the patients were JAK2 V617F positive prior to the SCT (mean mutation levels 74%, range 16–98%). After the procedure, the mutation levels progressively decreased and were in correlation with the donor–recipient chimerism status (r = 0.97, p < 0.001). At a median follow up of 16 months (range 2–58), 9/15 patients are alive and in CR. The levels of the JAK2 V617F mutation reached 0% in all surviving patients.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Leukemia Research - Volume 32, Issue 3, March 2008, Pages 421–427
Journal: Leukemia Research - Volume 32, Issue 3, March 2008, Pages 421–427
نویسندگان
Maya Koren-Michowitz, Avichai Shimoni, Asaf Vivante, Luba Trakhtenbrot, Gideon Rechavi, Ninette Amariglio, Ron Loewenthal, Arnon Nagler, Yoram Cohen,